Table 3.
Antifungal susceptibility profile of 320 oral yeast isolates from HIV-infected patients from Kunming, China
| Species (No.) | Antifungal agent | MIC range (μg/mL) | No. of S strains (%)a | No. of S-DD strains (%)b | No. of R strains (%)c |
|---|---|---|---|---|---|
|
C. albicans (263) |
Fluconazole |
0.125-64 |
251 (95.0) |
3 (1.1) |
9 (3.4) |
| |
Itraconazole |
0.031-16 |
232 (88.2) |
13 (4.9) |
18 (6.8) |
| |
Voriconazole |
0.031-16 |
255 (97.0) |
- |
8 (3.0) |
| |
Amphotericin B |
0.125-1 |
263 (100.0) |
- |
0 (0) |
|
C. glabrata (29) |
Fluconazole |
0.25-64 |
23 (79.3) |
1 (3.4) |
5 (17.2) |
| |
Itraconazole |
0.031-16 |
7 (24.1) |
7 (24.1) |
15 (51.7) |
| |
Voriconazole |
0.031-16 |
25 (86.2) |
- |
4 (13.8) |
| |
Amphotericin B |
0.25-1 |
29 (100.0) |
- |
0 (0) |
|
C. krusei (10) |
Fluconazole |
8-64 |
3 (30.0) |
5 (50.0) |
2 (20.0) |
| |
Itraconazole |
0.125-4 |
1 (10.0) |
3 (30.0) |
6 (60.0) |
| |
Voriconazole |
0.063-2 |
8 (80.0) |
- |
2 (20.0) |
| |
Amphotericin B |
0.25-1 |
10 (100.0) |
- |
0 (0) |
|
C. tropicalis (2) |
Fluconazole |
64 |
0 (0) |
0 (0) |
2 (100) |
| |
Itraconazole |
16 |
0 (0) |
0 (0) |
2 (100) |
| |
Voriconazole |
16 |
0 (0) |
- |
2 (100) |
| |
Amphotericin B |
0.5-1 |
2 (100.0) |
- |
0 (0) |
|
C. parapsilosis (12) |
Fluconazole |
0.125-1 |
12 (100.0) |
0 (0) |
0 (0) |
| |
Itraconazole |
0.031-2 |
6 (50.0) |
4 (33.3) |
2 (16.7) |
| |
Voriconazole |
0.031 |
12 (100.0) |
- |
0 (0) |
| |
Amphotericin B |
0.25-1 |
12 (100.0) |
- |
0 (0) |
|
C. rugosa (1) |
Fluconazole |
1 |
1 (100.0) |
0 (0) |
0 (0) |
| |
Itraconazole |
0.031 |
1 (100.0) |
0 (0) |
0 (0) |
| |
Voriconazole |
0.031 |
1 (100.0) |
- |
0 (0) |
| |
Amphotericin B |
0.5 |
1 (100.0) |
- |
0 (0) |
|
C. norvegensis (1) |
Fluconazole |
1 |
1 (100.0) |
0 (0) |
0 (0) |
| |
Itraconazole |
0.25 |
1 (100.0) |
0 (0) |
0 (0) |
| |
Voriconazole |
0.063 |
1 (100.0) |
- |
0 (0) |
| |
Amphotericin B |
1 |
1 (100.0) |
- |
0 (0) |
|
Pichia ohmeri (1) |
Fluconazole |
8 |
1 (100.0) |
0 (0) |
0 (0) |
| |
Itraconazole |
2 |
0 (0) |
0 (0) |
1 (100) |
| |
Voriconazole |
0.125 |
1 (100.0) |
- |
0 (0) |
| |
Amphotericin B |
0.5 |
1 (100.0) |
- |
0 (0) |
|
Saccharomyces cerevisiae (1) |
Fluconazole |
16 |
0 (0) |
1 (100.0) |
0 (0) |
| |
Itraconazole |
0.25 |
0 (0) |
1 (100.0) |
0 (0) |
| |
Voriconazole |
0.125 |
1 (100.0) |
- |
0 (0) |
| Amphotericin B | 1 | 1 (100.0) | - | 0 (0) |
a Susceptible (S) strains were defined by MIC ≤8 μg/mL for fluconazole, ≤0.125 μg/mL for itraconazole, <1 μg/mL for voriconazole and ≤ 1 μg/mL for amphotericin B.
b Susceptible-dose dependent (S-DD) strains were defined by MICs between 16 μg/mL and 32 μg/mL for fluconazole and between 0.25 μg/mL and 0.5 μg/mL for itraconazole.
c Resistant (R) strains were defined by MIC ≥64 μg/mL for fluconazole, ≥1 μg/mL for itraconazole and voriconazole, and >1 μg/mL for amphotericin B.